FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3131797462> ?p ?o ?g. }

• W3131797462 endingPage "10" @default.
• W3131797462 startingPage "PS5" @default.
• W3131797462 abstract "Abstract Background: CDK4/6 inhibitors have emerged as the standard of care for HR+ MBC. However, there is limited insight into the potential benefit of abemaciclib following prior progression on palbociclib or ribociclib. Based on a multi-center cohort of patients with HR+ MBC who had received abemaciclib after prior palbociclib progression (Wander SA et al ASCO 2019), we have previously reported that abemaciclib after prior CDK4/6i progression was well tolerated and that a subset of patients derived durable clinical benefit. Identifying molecular predictors of sensitivity to abemaciclib after prior CDK4/6i progression constitutes an important area of research. Given the high frequency of ESR1 mutations in HR+ MBC with antiestrogen resistance, we evaluated the translational impact of ESR1 mutations in mediating response to abemaciclib in this setting. Methods: To evaluate abemaciclib sensitivity in ESR1 mutant cell lines, T47D HR+ breast cancer cells were modified to over-express multiple mutant ESR1 isoforms via lentiviral infection and antibiotic selection. These isoforms included ESR1 Y537S, Y537N, and D538G. In an additional T47D cell line, RB1 expression was knocked down via CRISPR. The resulting derivative cell lines were grown in the absence of estrogen (via charcoal-stripped serum, CSS) or in escalating doses of abemaciclib. Cell viability was measured via cell-titer-glo assay. For clinical validation, we identified patients with MBC who had ESR1 mutations detected by targeted sequencing of cell-free DNA (cfDNA), via CLIA certified Guardant assay, and had abemaciclib exposure following prior progression on palbociclib or ribociclib in the existing multi-center cohort from six US institutions. Results: All ESR1 mutant derivative cells demonstrated enhanced growth in estrogen deprivation compared to GFP controls, as expected, and were similarly sensitive to escalating doses of abemaciclib monotherapy in vitro, suggesting that ESR1 mutations do not confer resistance to abemaciclib. Interestingly, two patients with ESR1 mutations (in the absence of concurrent driver alterations in RB1, FGFR, CCNE2, and ERBB2) demonstrated progression on palbociclib and sensitivity to abemaciclib. In one patient, cfDNA obtained prior to palbociclib and fulvestrant exposure failed to reveal any ESR1 alteration. Following progression on palbociclib, and prior to sequential exposure to abemaciclib, an ESR1 Y537N alteration was identified. The patient went on to receive 16 months of abemaciclib monotherapy. In a second patient, an ESR1 D538G alteration was identified following progression on palbociclib and fulvestrant. The patient had several intervening regimens, and subsequently went on to receive abemaciclib and fulvestrant for 16 months. RB1-null T47D cells were resistant to abemaciclib monotherapy in vitro, as expected and, in the clinical dataset, the presence of alterations in previously identified genomic mediators of CDK4/6i resistance, such as RB1, were associated with progression on both palbociclib and abemaciclib. Conclusions: HR+ breast cancer cells expressing mutant ESR1 isoforms were resistant to estrogen deprivation but retained sensitivity to abemaciclib in vitro. Furthermore, patients harboring ESR1 mutations via targeted sequencing of cfDNA, in the absence of other known mediators of CDK4/6i resistance, were shown to derive clinical benefit from abemaciclib following prior progression on palbociclib. These results suggest that patients with HR+ MBC, ESR1 mutation, and clinical resistance to anti-estrogen treatment and palbociclib may be candidates for abemaciclib treatment. Further research is warranted to confirm these novel translational observations. Citation Format: Seth A. Wander, Hyo S. Han, Gabriela N. Johnson, Maxwell R. Lloyd, Pingping Mao, Utthara Nayar, Kailey Kowalski, Casey R. Stein, Veronica Mariotti, Leslie SL Kim, Maren Levin, Jing Xi, Apurva Pandey, Siobhan Dunne, Azadeh Nasrazadani, Adam Brufsky, Kevin Kalinsky, Cynthia X Ma, Joyce O’Shaughnessy, Nikhil Wagle, Aditya Bardia. Esr1 mutation as a potential predictor of abemaciclib benefit following prior cdk4/6 inhibitor (cdk4/6i) progression in hormone receptor-positive (hr+) metastatic breast cancer (mbc): A translational investigation [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS5-10." @default.
• W3131797462 created "2021-03-01" @default.
• W3131797462 creator A5003261106 @default.
• W3131797462 creator A5003429913 @default.
• W3131797462 creator A5009199118 @default.
• W3131797462 creator A5010823002 @default.
• W3131797462 creator A5011630205 @default.
• W3131797462 creator A5020013190 @default.
• W3131797462 creator A5025351031 @default.
• W3131797462 creator A5031004196 @default.
• W3131797462 creator A5034972183 @default.
• W3131797462 creator A5044108002 @default.
• W3131797462 creator A5044389479 @default.
• W3131797462 creator A5055422485 @default.
• W3131797462 creator A5055781858 @default.
• W3131797462 creator A5055952938 @default.
• W3131797462 creator A5059240684 @default.
• W3131797462 creator A5061751852 @default.
• W3131797462 creator A5065605015 @default.
• W3131797462 creator A5068721624 @default.
• W3131797462 creator A5071432873 @default.
• W3131797462 creator A5083365013 @default.
• W3131797462 creator A5083426638 @default.
• W3131797462 date "2021-02-15" @default.
• W3131797462 modified "2023-10-06" @default.
• W3131797462 title "Abstract PS5-10: <i>Esr1</i> mutation as a potential predictor of abemaciclib benefit following prior cdk4/6 inhibitor (cdk4/6i) progression in hormone receptor-positive (hr+) metastatic breast cancer (mbc): A translational investigation" @default.
• W3131797462 doi "https://doi.org/10.1158/1538-7445.sabcs20-ps5-10" @default.
• W3131797462 hasPublicationYear "2021" @default.
• W3131797462 type Work @default.
• W3131797462 sameAs 3131797462 @default.
• W3131797462 citedByCount "1" @default.
• W3131797462 countsByYear W31317974622021 @default.
• W3131797462 crossrefType "journal-article" @default.
• W3131797462 hasAuthorship W3131797462A5003261106 @default.
• W3131797462 hasAuthorship W3131797462A5003429913 @default.
• W3131797462 hasAuthorship W3131797462A5009199118 @default.
• W3131797462 hasAuthorship W3131797462A5010823002 @default.
• W3131797462 hasAuthorship W3131797462A5011630205 @default.
• W3131797462 hasAuthorship W3131797462A5020013190 @default.
• W3131797462 hasAuthorship W3131797462A5025351031 @default.
• W3131797462 hasAuthorship W3131797462A5031004196 @default.
• W3131797462 hasAuthorship W3131797462A5034972183 @default.
• W3131797462 hasAuthorship W3131797462A5044108002 @default.
• W3131797462 hasAuthorship W3131797462A5044389479 @default.
• W3131797462 hasAuthorship W3131797462A5055422485 @default.
• W3131797462 hasAuthorship W3131797462A5055781858 @default.
• W3131797462 hasAuthorship W3131797462A5055952938 @default.
• W3131797462 hasAuthorship W3131797462A5059240684 @default.
• W3131797462 hasAuthorship W3131797462A5061751852 @default.
• W3131797462 hasAuthorship W3131797462A5065605015 @default.
• W3131797462 hasAuthorship W3131797462A5068721624 @default.
• W3131797462 hasAuthorship W3131797462A5071432873 @default.
• W3131797462 hasAuthorship W3131797462A5083365013 @default.
• W3131797462 hasAuthorship W3131797462A5083426638 @default.
• W3131797462 hasConcept C121608353 @default.
• W3131797462 hasConcept C126322002 @default.
• W3131797462 hasConcept C143998085 @default.
• W3131797462 hasConcept C2775930923 @default.
• W3131797462 hasConcept C2779744173 @default.
• W3131797462 hasConcept C502942594 @default.
• W3131797462 hasConcept C530470458 @default.
• W3131797462 hasConcept C71924100 @default.
• W3131797462 hasConcept C84606932 @default.
• W3131797462 hasConceptScore W3131797462C121608353 @default.
• W3131797462 hasConceptScore W3131797462C126322002 @default.
• W3131797462 hasConceptScore W3131797462C143998085 @default.
• W3131797462 hasConceptScore W3131797462C2775930923 @default.
• W3131797462 hasConceptScore W3131797462C2779744173 @default.
• W3131797462 hasConceptScore W3131797462C502942594 @default.
• W3131797462 hasConceptScore W3131797462C530470458 @default.
• W3131797462 hasConceptScore W3131797462C71924100 @default.
• W3131797462 hasConceptScore W3131797462C84606932 @default.
• W3131797462 hasIssue "4_Supplement" @default.
• W3131797462 hasLocation W31317974621 @default.
• W3131797462 hasOpenAccess W3131797462 @default.
• W3131797462 hasPrimaryLocation W31317974621 @default.
• W3131797462 hasRelatedWork W2480965698 @default.
• W3131797462 hasRelatedWork W2731600971 @default.
• W3131797462 hasRelatedWork W2769683585 @default.
• W3131797462 hasRelatedWork W2802389486 @default.
• W3131797462 hasRelatedWork W2810688799 @default.
• W3131797462 hasRelatedWork W3161515104 @default.
• W3131797462 hasRelatedWork W3203106735 @default.
• W3131797462 hasRelatedWork W4200136212 @default.
• W3131797462 hasRelatedWork W4254399222 @default.
• W3131797462 hasRelatedWork W4385476556 @default.
• W3131797462 hasVolume "81" @default.
• W3131797462 isParatext "false" @default.
• W3131797462 isRetracted "false" @default.
• W3131797462 magId "3131797462" @default.
• W3131797462 workType "article" @default.